Is BRNS or BMEA more profitable?

Barinthus Biotherapeutics' return on equity of -59.15% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -59.15% -43.80% Biomea Fusion N/A -253.73% -97.91%

Is BRNS or ACET more profitable?

Barinthus Biotherapeutics' return on equity of -59.15% beat Adicet Bio's return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -59.15% -43.80% Adicet Bio N/A -74.90% -60.87%

Do analysts recommend BRNS or RLYB?

Barinthus Biotherapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 611.62%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Barinthus Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend BRNS or TELO?

Barinthus Biotherapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 611.62%. Given Barinthus Biotherapeutics' higher probable upside, equities research analysts clearly believe Barinthus Biotherapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Barinthus Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BRNS or TELO more profitable?

Barinthus Biotherapeutics' return on equity of -59.15% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -59.15% -43.80% Telomir Pharmaceuticals N/A -201.23% -172.71%

Barinthus Biotherapeutics (BRNS) Competitors

$0.56 -0.04 (-6.16%)

Closing price 08/10/2026 03:59 PM Eastern

Extended Trading

$0.58 +0.02 (+3.90%)

As of 07:00 AM Eastern

Compare

BRNS vs. BMEA, ACET, RLYB, TELO, and ATRA

Should you buy Barinthus Biotherapeutics stock or one of its competitors? Barinthus Biotherapeutics's main competitors and comparable companies include Biomea Fusion (BMEA), Adicet Bio (ACET), Rallybio (RLYB), Telomir Pharmaceuticals (TELO), and Atara Biotherapeutics (ATRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Barinthus Biotherapeutics compare to Biomea Fusion?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

In the previous week, Biomea Fusion had 9 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 10 mentions for Biomea Fusion and 1 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 1.50 beat Biomea Fusion's score of 0.94 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Very Positive
Biomea Fusion	Positive

Barinthus Biotherapeutics' return on equity of -59.15% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
Biomea Fusion	N/A	-253.73%	-97.91%

Barinthus Biotherapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.28, meaning that its share price is 128% less volatile than the broader market.

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 8.5% of Barinthus Biotherapeutics shares are owned by company insiders. Comparatively, 10.6% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Biomea Fusion has lower revenue, but higher earnings than Barinthus Biotherapeutics. Biomea Fusion is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.53	-$66.43M	-$1.03	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.29	N/A

Barinthus Biotherapeutics currently has a consensus target price of $4.00, indicating a potential upside of 611.62%. Biomea Fusion has a consensus target price of $8.20, indicating a potential upside of 545.67%. Given Barinthus Biotherapeutics' higher possible upside, research analysts plainly believe Barinthus Biotherapeutics is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Biomea Fusion beats Barinthus Biotherapeutics on 8 of the 14 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Adicet Bio?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Adicet Bio (NASDAQ:ACET) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Barinthus Biotherapeutics' return on equity of -59.15% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
Adicet Bio	N/A	-74.90%	-60.87%

Barinthus Biotherapeutics has higher revenue and earnings than Adicet Bio. Adicet Bio is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.53	-$66.43M	-$1.03	N/A
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A

Barinthus Biotherapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market. Comparatively, Adicet Bio has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 83.9% of Adicet Bio shares are held by institutional investors. 8.5% of Barinthus Biotherapeutics shares are held by insiders. Comparatively, 3.4% of Adicet Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Barinthus Biotherapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 611.62%. Adicet Bio has a consensus price target of $46.80, suggesting a potential upside of 477.07%. Given Barinthus Biotherapeutics' higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Adicet Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Adicet Bio had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 3 mentions for Adicet Bio and 1 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 1.50 beat Adicet Bio's score of -0.26 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Very Positive
Adicet Bio	Neutral

Summary

Barinthus Biotherapeutics beats Adicet Bio on 9 of the 15 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Rallybio?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Rallybio (NASDAQ:RLYB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Rallybio has lower revenue, but higher earnings than Barinthus Biotherapeutics. Rallybio is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.53	-$66.43M	-$1.03	N/A
Rallybio	$860K	102.56	-$8.98M	-$4.34	N/A

Barinthus Biotherapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market.

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 8.5% of Barinthus Biotherapeutics shares are held by insiders. Comparatively, 10.3% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Rallybio had 1 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 2 mentions for Rallybio and 1 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 1.50 beat Rallybio's score of 1.06 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Very Positive
Rallybio	Positive

Barinthus Biotherapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -40.53% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
Rallybio	-911.07%	-40.53%	-38.13%

Barinthus Biotherapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 611.62%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Barinthus Biotherapeutics beats Rallybio on 9 of the 16 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Telomir Pharmaceuticals?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 8.5% of Barinthus Biotherapeutics shares are owned by company insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Telomir Pharmaceuticals has lower revenue, but higher earnings than Barinthus Biotherapeutics. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.53	-$66.43M	-$1.03	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

Barinthus Biotherapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 611.62%. Given Barinthus Biotherapeutics' higher probable upside, equities research analysts clearly believe Barinthus Biotherapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Telomir Pharmaceuticals had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 1 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 1.50 beat Telomir Pharmaceuticals' score of -0.81 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Very Positive
Telomir Pharmaceuticals	Negative

Barinthus Biotherapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

Barinthus Biotherapeutics' return on equity of -59.15% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Summary

Barinthus Biotherapeutics beats Telomir Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Atara Biotherapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Barinthus Biotherapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market.

Barinthus Biotherapeutics presently has a consensus target price of $4.00, indicating a potential upside of 611.62%. Atara Biotherapeutics has a consensus target price of $9.50, indicating a potential upside of 10.34%. Given Barinthus Biotherapeutics' higher probable upside, research analysts clearly believe Barinthus Biotherapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Atara Biotherapeutics has higher revenue and earnings than Barinthus Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.53	-$66.43M	-$1.03	N/A
Atara Biotherapeutics	$120.77M	0.64	$32.69M	-$0.67	N/A

In the previous week, Atara Biotherapeutics had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 1 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 1.50 beat Atara Biotherapeutics' score of -0.09 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Very Positive
Atara Biotherapeutics	Neutral

Barinthus Biotherapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Barinthus Biotherapeutics' return on equity of -59.15% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 8.5% of Barinthus Biotherapeutics shares are held by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Atara Biotherapeutics beats Barinthus Biotherapeutics on 8 of the 14 factors compared between the two stocks.

Get Barinthus Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRNS vs. The Competition

Export

Metric	Barinthus Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.47M	$3.70B	$7.01B	$12.98B
Dividend Yield	N/A	3.77%	2.58%	10.06%
P/E Ratio	-0.55	9.09	269.18	24.72
Price / Sales	1.53	1,260.17	585.57	96.21
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	0.31	18.06	11.40	6.42
Net Income	-$66.43M	-$13.25M	$3.45B	$347.03M
7 Day Performance	-4.24%	3.15%	1.96%	0.71%
1 Month Performance	-10.35%	-1.65%	-0.55%	-0.87%
1 Year Performance	-50.69%	61.81%	75.51%	21.94%

Barinthus Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRNS Barinthus Biotherapeutics	3.1524 of 5 stars	$0.56 -6.2%	$4.00 +611.6%	-58.1%	$24.47M	$14.97M	N/A	107	Positive News Earnings Report
BMEA Biomea Fusion	2.7029 of 5 stars	$1.26 +2.4%	$8.50 +574.6%	-17.5%	$88.93M	N/A	N/A	50	News Coverage Earnings Report Analyst Revision
ACET Adicet Bio	3.5012 of 5 stars	$9.11 -1.1%	$48.80 +435.7%	-18.4%	$86.10M	N/A	N/A	90	Earnings Report
RLYB Rallybio	1.7264 of 5 stars	$16.14 +1.1%	N/A	+291.0%	$84.56M	$860K	N/A	40	Positive News Earnings Report
TELO Telomir Pharmaceuticals	0.1715 of 5 stars	$1.18 +2.6%	N/A	-25.0%	$79.09M	N/A	N/A	1	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRNS) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. BMEA, ACET, RLYB, TELO, and ATRA

How does Barinthus Biotherapeutics compare to Biomea Fusion?

Summary

How does Barinthus Biotherapeutics compare to Adicet Bio?

Summary

How does Barinthus Biotherapeutics compare to Rallybio?

Summary

How does Barinthus Biotherapeutics compare to Telomir Pharmaceuticals?

Summary

How does Barinthus Biotherapeutics compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. BMEA, ACET, RLYB, TELO, and ATRA

How does Barinthus Biotherapeutics compare to Biomea Fusion?

Does the media favor BRNS or BMEA?

Is BRNS or BMEA more profitable?

Which has more volatility & risk, BRNS or BMEA?

Do institutionals and insiders believe in BRNS or BMEA?

Which has higher earnings & valuation, BRNS or BMEA?

Do analysts rate BRNS or BMEA?

Summary

How does Barinthus Biotherapeutics compare to Adicet Bio?

Is BRNS or ACET more profitable?

Which has higher valuation & earnings, BRNS or ACET?

Which has more volatility & risk, BRNS or ACET?

Do institutionals & insiders have more ownership in BRNS or ACET?

Do analysts prefer BRNS or ACET?

Does the media favor BRNS or ACET?

Summary

How does Barinthus Biotherapeutics compare to Rallybio?

Which has preferable valuation and earnings, BRNS or RLYB?

Which has more risk and volatility, BRNS or RLYB?

Do insiders and institutionals hold more shares of BRNS or RLYB?

Does the media prefer BRNS or RLYB?

Is BRNS or RLYB more profitable?

Do analysts recommend BRNS or RLYB?

Summary

How does Barinthus Biotherapeutics compare to Telomir Pharmaceuticals?

Do insiders and institutionals hold more shares of BRNS or TELO?

Which has preferable earnings & valuation, BRNS or TELO?

Do analysts recommend BRNS or TELO?

Does the media prefer BRNS or TELO?

Which has more volatility & risk, BRNS or TELO?

Is BRNS or TELO more profitable?

Summary

How does Barinthus Biotherapeutics compare to Atara Biotherapeutics?

Which has more volatility and risk, BRNS or ATRA?

Do analysts prefer BRNS or ATRA?

Which has better earnings & valuation, BRNS or ATRA?

Does the media prefer BRNS or ATRA?

Is BRNS or ATRA more profitable?

Do insiders & institutionals believe in BRNS or ATRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools